☐ |
Form 20-F
|
☒
|
Form 40-F |
|
BELLUS Health Inc. | ||
|
|||
|
|||
Date: November 10, 2021
|
By:
|
/s/ Ramzi Benamar
|
|
Name: Ramzi Benamar
|
|||
Title: Chief Financial Officer
|
Exhibit
Number
|
Document Description
|
|
|
|
|
|
![]() |
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
|
•
|
In September 2021, the Company announced positive findings from a preplanned administrative interim analysis of the SOOTHE trial. A predefined stringent probability threshold for clinical efficacy was met for at least one and up to
all three doses of BLU-5937 tested. Limited taste-related adverse events were observed, consistent with previous BLU-5937 trials, and no serious adverse events were reported.
|
•
|
As of September 2021, the Company completed participant enrollment in the SOOTHE trial with a total of 310 participants with RCC enrolled, including 249 participants in the main trial and 61 in the exploratory group.
|
•
|
Topline results are expected in December 2021.
|
•
|
The positive findings from the SOOTHE trial interim analysis enabled the Company to accelerate the planning for its Phase 3 program while awaiting the SOOTHE trial’s final results.
|
•
|
As of September 2021, the Company completed participant enrollment in the BLUEPRINT trial, with a total of 142 participants with moderate to severe chronic pruritus associated with mild to moderate AD enrolled.
|
•
|
Topline results are expected in December 2021.
|
![]() |
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
|
•
|
Additional data from the Phase 2a RELIEF trial was presented in an oral presentation at ERS, which was held September 5-8, 2021. The presentation reviewed the observed improvements seen in cough severity and quality of life
over a 16-day treatment period that favored BLU-5937.
|
•
|
On November 15, 2021, the Company is planning to host an Analyst Event to discuss topics including the RCC landscape, clinical development updates for BLU-5937, RCC market dynamics and P2X3 antagonist platform potential. The
event will be hosted virtually, and a replay of the event will be available on the Events & Presentations page of the Company’s website.
|
•
|
Current cash position is expected to be sufficient to fund the Company’s operating plan until the end of 2022.
|
![]() |
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
|
Three months ended
September 30, 2021
|
Three months ended
September 30, 2020
|
|||||
(in thousands of dollars, except per share data)
|
||||||
Revenues
|
US$
|
4 |
US$
|
3 | ||
Research and development expenses, net
|
(19,054)
|
|
(5,796)
|
|
||
General and administrative expenses
|
(3,821)
|
|
(456)
|
|
||
Net finance (costs) income
|
(10)
|
|
540 | |||
Net loss for the period
|
US$
|
(22,881)
|
|
US$
|
(5,709)
|
|
Basic and diluted loss per share
|
US$
|
(0.29)
|
|
US$
|
(0.09)
|
|
![]() |
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
|
![]() |
BELLUS Health Inc.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
|